Table 1.
Summary of human apolipoprotein characteristics
| Apolipoprotein | UniProt Accession |
Gene Loci |
Molecular Weight (KDa) | Plasma levels (mg/dL) | Functiona |
|---|---|---|---|---|---|
| ApoA-I | P02647 | 11q23.3 | 31.7 | 90–130 | Cofactor for LCAT |
| ApoA-II | P02652 | 1q23.3 | 11.1 | 30–50 | Inhibit LPL Displace ApoA-I |
| ApoA-IV | P06727 | 11q23.3 | 45.4 | 15–40 | Modulate LPL Activate LCAT |
| ApoA-V | Q6Q788 | 11q23.3 | 41.2 | 0.025–0.040 | Modulate LPL Activate LCAT |
| ApoB-100 | P04114 | 2p24.1 | 515.6 | 90–100 | Ligand for LDL receptor |
| Apo(a) | P08519 | 6q25.3–26 | 250–800 | ∼2–10 | Anti-angiogenic |
| ApoC-I | P02654 | 19q13.32 | 9.3 | ∼6 | Activate LCAT Inhibitor of LPL, CETP |
| ApoC-II | P02655 | 19q13.32 | 11.2 | 2–6 | Activate LPL |
| ApoC-III | P02656 | 11q23.3 | 10.8 | ∼12 | Inhibitor of LPL, displace ApoE from LDL receptor |
| ApoC-IV | P55056 | 19q13.32 | 14.5 | 0.1–2 | unclear |
| ApoD | P05090 | 13q29 | 21.3 | 5–25 | Cofactor for LCAT, LPL |
| ApoE | P02649 | 19q13.32 | 36.2 | 3–8 | Modulate LCAT, CETP, LPL. Ligand for LDL receptor |
| ApoF | Q13790 | 12q13.3 | 35.4 | 8–13 | Inhibit CETP |
| ApoH | P02749 | 17q24.2 | 38.3 | 5–60 | unclear |
| ApoJ | P10909 | 8p21.1 | 52.5 | ∼9 | unclear |
| ApoL-1 | O14791 | 22q12.3 | 43.9 | 0.85 | unclear |
| ApoM | O95445 | 6p21.33 | 21.2 | 2–5 | HDL metabolism |
| ApoO | Q9BUR5 | Xp22.11 | 22.5 | 0.22 | unclear |
a
LCAT = Lecithin Cholesterol Acyl Transferase; LPL = Lipoprotein lipase; CETP = Cholesterol ester transfer protein; LDL- R = Low Density lipoprotein receptor.